Template:Travelers Diarrhea Antibiotics: Difference between revisions
Ostermayer (talk | contribs) (Created page with "*Ciprofloxacin 750mg PO BID x 1-3 days<ref>Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1...") |
No edit summary |
||
| Line 1: | Line 1: | ||
*[[Ciprofloxacin]] 750mg PO | *[[Ciprofloxacin]] 750mg PO once daily x 1-3 days<ref>Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5</ref> | ||
*[[ | **First choice for use except in South and Southeast Asia | ||
* | *[[Azithromycin]] 500mg PO q24h x 3 days OR 1000mg PO x 1<ref>Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8</ref> | ||
**Nausea is a frequent adverse event | |||
**First choice for use in South and Southeast Asia | |||
*[[Rifaximin]] 200mg PO TID x 3 days<ref>DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15</ref> | *[[Rifaximin]] 200mg PO TID x 3 days<ref>DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15</ref> | ||
*[[ | **Ineffective against mucosally invasive pathogens ([[Shigella]], [[Salmonella]], [[Campylobacter]]) | ||
**Considered very safe as it is not absorbed | |||
Revision as of 21:53, 6 January 2015
- Ciprofloxacin 750mg PO once daily x 1-3 days[1]
- First choice for use except in South and Southeast Asia
- Azithromycin 500mg PO q24h x 3 days OR 1000mg PO x 1[2]
- Nausea is a frequent adverse event
- First choice for use in South and Southeast Asia
- Rifaximin 200mg PO TID x 3 days[3]
- Ineffective against mucosally invasive pathogens (Shigella, Salmonella, Campylobacter)
- Considered very safe as it is not absorbed
- ↑ Hoge CW. et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341–5
- ↑ Sanders JW. et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg. 2002;67:533–8
- ↑ DuPont HL. et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807–15
